Zacks Investment Research lowered shares of Catalent (NYSE:CTLT) from a hold rating to a sell rating in a research report sent to investors on Monday.
According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
Other research analysts also recently issued reports about the company. ValuEngine downgraded Catalent from a buy rating to a hold rating in a research note on Tuesday, June 5th. JPMorgan Chase & Co. boosted their target price on Catalent from $50.00 to $55.00 and gave the stock an overweight rating in a research note on Wednesday, August 29th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have issued a buy rating to the company. The company has a consensus rating of Buy and an average target price of $48.09.
Shares of CTLT stock opened at $41.69 on Monday. Catalent has a 1-year low of $36.73 and a 1-year high of $47.87. The company has a current ratio of 2.15, a quick ratio of 1.79 and a debt-to-equity ratio of 2.44. The firm has a market cap of $6.06 billion, a P/E ratio of 26.06, a price-to-earnings-growth ratio of 2.49 and a beta of 1.42.
Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, August 28th. The company reported $0.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.61 by $0.06. Catalent had a return on equity of 20.42% and a net margin of 3.39%. The firm had revenue of $685.30 million for the quarter, compared to the consensus estimate of $690.69 million. During the same period in the previous year, the business earned $0.65 EPS. The firm’s revenue for the quarter was up 11.1% on a year-over-year basis. equities research analysts forecast that Catalent will post 1.72 earnings per share for the current fiscal year.
In other Catalent news, SVP Steven L. Fasman sold 2,252 shares of Catalent stock in a transaction dated Wednesday, June 20th. The stock was sold at an average price of $41.78, for a total transaction of $94,088.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.70% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC lifted its position in Catalent by 4.3% during the 2nd quarter. Janus Henderson Group PLC now owns 6,400,737 shares of the company’s stock worth $268,127,000 after acquiring an additional 266,183 shares during the period. FMR LLC lifted its position in Catalent by 1.5% during the 2nd quarter. FMR LLC now owns 3,781,793 shares of the company’s stock worth $158,420,000 after acquiring an additional 54,678 shares during the period. Champlain Investment Partners LLC lifted its position in Catalent by 19.2% during the 1st quarter. Champlain Investment Partners LLC now owns 3,627,390 shares of the company’s stock worth $148,941,000 after acquiring an additional 583,675 shares during the period. American Century Companies Inc. lifted its position in Catalent by 6.4% during the 2nd quarter. American Century Companies Inc. now owns 3,052,515 shares of the company’s stock worth $127,870,000 after acquiring an additional 183,880 shares during the period. Finally, Earnest Partners LLC lifted its holdings in shares of Catalent by 0.3% in the 2nd quarter. Earnest Partners LLC now owns 2,548,094 shares of the company’s stock valued at $106,740,000 after buying an additional 7,628 shares during the period. 99.90% of the stock is owned by institutional investors.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Further Reading: Marijuana Stocks Investing Considerations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.